Tyng‐Yuan Jang, Batbold Batsaikhan, Yo‐Chia Chen, Chia‐Yen Dai
{"title":"低病毒载量慢性乙型肝炎患者的乙肝表面抗原丢失情况","authors":"Tyng‐Yuan Jang, Batbold Batsaikhan, Yo‐Chia Chen, Chia‐Yen Dai","doi":"10.1111/jgh.16667","DOIUrl":null,"url":null,"abstract":"Background and AimAmong low viral load (DNA of hepatitis B virus (HBV) was < 2000 IU/mL), the factor of the loss of hepatitis B surface antigen (HBsAg) remained elusive.MethodsThe retrospective study recruited patients with chronic hepatitis B (CHB) who were negative low for hepatitis B e‐antigen (HBeAg), had a low viral load, and experienced HBsAg loss during follow‐up. CHB patients with low‐viral load but without consequent HBsAg loss were also enrolled at the ratio of 1:4. The factors contributing to HBsAg loss were analyzed.ResultsA total of 80 patients were recruited for the current study, with a mean age of 63.9 years and 61.3% being male. Among them, 62.5% patients (50/80) were treated with potent nucleoside/nucleotide analogues (NAs) during the follow‐up period. Additionally, 12.5% patients (10/80) had a prior history of NAs treatment before enrolment. During the follow‐up, HBsAg loss occurred in 17 patients (21.3%). Compared with patients without HBsAg loss, those with HBsAg loss were younger (57.9 years <jats:italic>vs</jats:italic> 65.5 years; <jats:italic>P</jats:italic> = 0.01), had lower HBV DNA levels (1.3 log<jats:sub>10</jats:sub> IU/mL <jats:italic>vs</jats:italic> 2.3 log<jats:sub>10</jats:sub> IU/mL; <jats:italic>P</jats:italic> = 0.003), and higher proportion of prior NAs‐treated history. Logistic regression analysis revealed that the factors associated with factors associated with HBsAg loss were age < 60 years (OR/CI: 3.95/1.15–13.60, <jats:italic>P</jats:italic> = 0.03), prior NAs‐treated history (OR/CI: 7.59/1.42–40.51, <jats:italic>P</jats:italic> = 0.01) and current NAs‐treated (OR/CI: 0.19/0.05–0.71, <jats:italic>P</jats:italic> = 0.01).ConclusionsIn the study, older age and prior NAs were positively associated with HBsAg loss, and current NAs was negatively associated with HBsAg loss. Additionally, some patients experienced HBsAg loss during the NAs therapy.","PeriodicalId":15877,"journal":{"name":"Journal of Gastroenterology and Hepatology","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hepatitis B surface antigen loss in chronic hepatitis B patients with low‐viral‐load\",\"authors\":\"Tyng‐Yuan Jang, Batbold Batsaikhan, Yo‐Chia Chen, Chia‐Yen Dai\",\"doi\":\"10.1111/jgh.16667\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background and AimAmong low viral load (DNA of hepatitis B virus (HBV) was < 2000 IU/mL), the factor of the loss of hepatitis B surface antigen (HBsAg) remained elusive.MethodsThe retrospective study recruited patients with chronic hepatitis B (CHB) who were negative low for hepatitis B e‐antigen (HBeAg), had a low viral load, and experienced HBsAg loss during follow‐up. CHB patients with low‐viral load but without consequent HBsAg loss were also enrolled at the ratio of 1:4. The factors contributing to HBsAg loss were analyzed.ResultsA total of 80 patients were recruited for the current study, with a mean age of 63.9 years and 61.3% being male. Among them, 62.5% patients (50/80) were treated with potent nucleoside/nucleotide analogues (NAs) during the follow‐up period. Additionally, 12.5% patients (10/80) had a prior history of NAs treatment before enrolment. During the follow‐up, HBsAg loss occurred in 17 patients (21.3%). Compared with patients without HBsAg loss, those with HBsAg loss were younger (57.9 years <jats:italic>vs</jats:italic> 65.5 years; <jats:italic>P</jats:italic> = 0.01), had lower HBV DNA levels (1.3 log<jats:sub>10</jats:sub> IU/mL <jats:italic>vs</jats:italic> 2.3 log<jats:sub>10</jats:sub> IU/mL; <jats:italic>P</jats:italic> = 0.003), and higher proportion of prior NAs‐treated history. Logistic regression analysis revealed that the factors associated with factors associated with HBsAg loss were age < 60 years (OR/CI: 3.95/1.15–13.60, <jats:italic>P</jats:italic> = 0.03), prior NAs‐treated history (OR/CI: 7.59/1.42–40.51, <jats:italic>P</jats:italic> = 0.01) and current NAs‐treated (OR/CI: 0.19/0.05–0.71, <jats:italic>P</jats:italic> = 0.01).ConclusionsIn the study, older age and prior NAs were positively associated with HBsAg loss, and current NAs was negatively associated with HBsAg loss. Additionally, some patients experienced HBsAg loss during the NAs therapy.\",\"PeriodicalId\":15877,\"journal\":{\"name\":\"Journal of Gastroenterology and Hepatology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-06-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Gastroenterology and Hepatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/jgh.16667\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Gastroenterology and Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/jgh.16667","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景和目的在低病毒载量(乙型肝炎病毒(HBV)的 DNA 为 2000 IU/mL)患者中,乙型肝炎表面抗原(HBsAg)丢失的因素仍然难以确定。方法这项回顾性研究招募了乙型肝炎 e 抗原(HBeAg)低阴性、病毒载量低且在随访期间出现 HBsAg 丢失的慢性乙型肝炎(CHB)患者。病毒载量低但未因此导致 HBsAg 消失的慢性乙型肝炎(CHB)患者也按 1:4 的比例被纳入研究。结果 本次研究共招募了 80 名患者,平均年龄为 63.9 岁,61.3% 为男性。其中,62.5%的患者(50/80)在随访期间接受过强效核苷/核苷酸类似物(NAs)治疗。此外,12.5% 的患者(10/80)在入组前曾接受过 NAs 治疗。在随访期间,有 17 名患者(21.3%)出现了 HBsAg 消失。与未丢失 HBsAg 的患者相比,丢失 HBsAg 的患者更年轻(57.9 岁 vs 65.5 岁;P = 0.01),HBV DNA 水平更低(1.3 log10 IU/mL vs 2.3 log10 IU/mL;P = 0.003),曾接受过 NAs 治疗的患者比例更高。逻辑回归分析显示,与 HBsAg 消失相关的因素有年龄 < 60 岁(OR/CI:3.95/1.15-13.60,P = 0.03)、既往 NAs 治疗史(OR/CI:7.59/1.42-40.结论在该研究中,年龄较大和既往NAs与HBsAg丢失呈正相关,而目前NAs与HBsAg丢失呈负相关。此外,一些患者在接受 NAs 治疗期间出现了 HBsAg 消失。
Hepatitis B surface antigen loss in chronic hepatitis B patients with low‐viral‐load
Background and AimAmong low viral load (DNA of hepatitis B virus (HBV) was < 2000 IU/mL), the factor of the loss of hepatitis B surface antigen (HBsAg) remained elusive.MethodsThe retrospective study recruited patients with chronic hepatitis B (CHB) who were negative low for hepatitis B e‐antigen (HBeAg), had a low viral load, and experienced HBsAg loss during follow‐up. CHB patients with low‐viral load but without consequent HBsAg loss were also enrolled at the ratio of 1:4. The factors contributing to HBsAg loss were analyzed.ResultsA total of 80 patients were recruited for the current study, with a mean age of 63.9 years and 61.3% being male. Among them, 62.5% patients (50/80) were treated with potent nucleoside/nucleotide analogues (NAs) during the follow‐up period. Additionally, 12.5% patients (10/80) had a prior history of NAs treatment before enrolment. During the follow‐up, HBsAg loss occurred in 17 patients (21.3%). Compared with patients without HBsAg loss, those with HBsAg loss were younger (57.9 years vs 65.5 years; P = 0.01), had lower HBV DNA levels (1.3 log10 IU/mL vs 2.3 log10 IU/mL; P = 0.003), and higher proportion of prior NAs‐treated history. Logistic regression analysis revealed that the factors associated with factors associated with HBsAg loss were age < 60 years (OR/CI: 3.95/1.15–13.60, P = 0.03), prior NAs‐treated history (OR/CI: 7.59/1.42–40.51, P = 0.01) and current NAs‐treated (OR/CI: 0.19/0.05–0.71, P = 0.01).ConclusionsIn the study, older age and prior NAs were positively associated with HBsAg loss, and current NAs was negatively associated with HBsAg loss. Additionally, some patients experienced HBsAg loss during the NAs therapy.
期刊介绍:
Journal of Gastroenterology and Hepatology is produced 12 times per year and publishes peer-reviewed original papers, reviews and editorials concerned with clinical practice and research in the fields of hepatology, gastroenterology and endoscopy. Papers cover the medical, radiological, pathological, biochemical, physiological and historical aspects of the subject areas. All submitted papers are reviewed by at least two referees expert in the field of the submitted paper.